维昇药业-B：截至2025年12月31日止年度年度业绩公告

2561 20251231 2025123120241231 123120252024 (lonapegsomatropin) •202542320244 •2025612Ascendis Pharma •202512DCD •2025116 •2026126®SKYTROFA®3322kDa≤306 •2026(lonapegsomatropin) (palopegteriparatide) •2025923(palopegteriparatide)202510 •2026132026NDA (navepegritide)C •2025512(navepegritide)25252 •20258241042(navepegritide) •2025122026310維藥業22026317 •202625(2228.HK) 201811(lonapegsomatropin)20261(lonapegsomatropin)PGHD183(lonapegsomatropin)(palopegteriparatide)(navepegritide)C * (1)2026126®SKYTROFA® (2)20231(palopegteriparatide)320261(3)(navepegritide)220231120244(4) (lonapegsomatropin) • (lonapegsomatropin)331752(lonapegsomatropin)5 2A H V3(lonapegsomatropin)201811A s c e n d i sP h a r m a( l o n a p e g s o m a t r o p i n )(lonapegsomatropin)-1(IGF-1)(lonapegsomatropin) • 2024420254 2026126®SKYTROFA®3322kDa≤306 • 2026®SKYTROFA®2026126 2026(lonapegsomatropin)(lonapegsomatropin) 20%80% (lonapegsomatropin)2 0(lonapegsomatropin)20252430(lonapegsomatropin) GSP202482025619 • (lonapegsomatropin)AscendisPharma 202310Ascendis Pharma2025612Ascendis Pharma (lonapegsomatropin)CDMO20237AscendisPharmaAscendisPharma202312CDMO2025122027 DCDDCDDCDDCDBLA2028 2025116 DCD DCDDCDDCD • 202536enliGHtenHormone Research inPaediatricsDOI: 10.1159/000545064(lonapegsomatropin)6 2025728AscendisPharmaFDASKYTROFA®lonapegsomatropin-tcgdTransCon hGH 18A.08(3)(lonapegsomatropin) (palopegteriparatide) (palopegteriparatide)201811AscendisPharma(palopegteriparatide)(palopegteriparatide)24(palopegteriparatide) 320231202613 • 2025923(palopegteriparatide)202510 2026132026NDA • 2025512Ascendis Pharma22144(palopegteriparatide) 2025714Ascendis PharmaPaTHway31563(palopegteriparatide) 2025117Ascendis Pharma2PaTH Forward3PaTHway(palopegteriparatide)3 18A.08(3)(palopegteriparatide) (navepegritide) • (navepegritide)210201811AscendisPharma(navepegritide)(navepegritide)(navepegritide)2 • 2025512(navepegritide)25252 20258241042(navepegritide)52AGV100μg CNP/kg(navepegritide)AGV5.939(P=0.018)4.760100 μg/kg(navepegritide)104ACHZ0.051040.199(navepegritide)Ascendis Pharma2 202512202631022026317 • 202569A s c e n d i sP h a r m aCOACH26(navepegritide)(lonapegsomatropin) 2025108Ascendis Pharma(navepegritide) 20251117Ascendis Pharma(navepegritide)ApproaCH52JAMAPediatrics(navepegritide)ApproaCH(navepegritide)52AGV 202618Ascendis PharmaCOACH52(navepegritide)(lonapegsomatropin)252(navepegritide)(lonapegsomatropin)(navepegritide)(lonapegsomatropin) 2026228Ascendis PharmaFDAYUVIWEL®(navepegritide)TransCon®CNP2CNP 18A.08(3)(navepegritide) 202625AI(2228.HK)AI 20255252020 202512313537%16 93.5 AscendisPharma60727(lonapegsomatropin)613 (lonapegsomatropin)Ascendis Pharma(lonapegsomatropin)962037928 (navepegritide)AscendisPharma(navepegritide)16312040210 (palopegteriparatide)Ascendis Pharma(palopegteriparatide)22252040619 Ascendis Pharma13102038629 261520203411204510 維藥業130631www.visenpharma.com3 2025123182 20251231144.42024123198.8 20251231 ••• •(TransCon)•• 18A.08(3) 20251231165(palopegteriparatide) 20251231146(palopegteriparatide) 2025123119 202412319.921.1%2025123111.95.020242.9 2025123114.9202412312.4 2024123190.53.03.3%2025123193.5 2024123186.433.2%20251231115.1(i)(ii) 2024202512311611,098 2024123117.445.0%202512319.6 2025123131.2 20241231182.239.1%20251231253.4 2025123120251231447.620251231632.620241231203.6 20251231 20251231 20251231 123120241231 202412314.3202512314.5 20251231170.12025123120241231100% 123120241231 20251231731.120241231170.4560.7 20251231202512315% 20251231 2025123120241231 Michael J.CHANG20258272025827 20258272025827 202562620258272025627827 2025101320251013 13.51B(1) C1 202512312 2F.1.3 2F.1.3Michael Wolff JENSEN2025627JensenJensen 3.213.22D.3YAO Zhengbin (Bing)20258272025827 2025123120251231 2025321672.3620.2 20251231229.3 (www.hkexnews.hk)(www.visenpharma.com) 20251231 20252024 5165–(146)–19– (253,422)(182,242) (253,422)(182,242) (253,447)(182,373) (253,447)(182,373) 9(2.44)(1.95) 20251231 20251231 1. 維藥業2018111P.O. Box 472, Harbour Place, 2nd Floor, 103 South Church Street, GeorgeTown, Grand Cayman KY1-1106, Cayman Islands 69B33-108 2. 3. 21 21 4. 8 5. 20252024 i.20251231916,0002024317,000 ii.202512311,082,0002024 7. 16.5%2024 25% 100% 120,00020% (Pillar Two model rules) 8. 2024 9. 202520241231202411 20252024(253,422)(182,242) 10. 20251231 11. 202520242,82583510,9959,31613,15812,1006,8084,792–9,0751,9402,67035,72638,788 12. 20252024 113,926,8642024102,976,8640.0001 20241120241231202511(a)(c)(c)(b) 20251231 20241120241231202511(c)(d) 20251231 *1,000 (a)20253211:1(b)2 0 2 532 111,385,0000.000168.80783,288,000723,209,810(c)20252VP EIP USLIMITED330,000(d)VP EIP NUS LIMITED765,000 20151620142272269 維藥業 2026312 (i)(ii)(iii)YAO Zhengbin (Bing)